Nagler, ArnonLabopin, MyriamSwoboda, RyszardPioltelli, PietroArat, MutluYakoub-Agha, IbrahimKulagin, AlexanderMaria Raiola, AnnaOzdogu, HakanRisitano, AntonioNur Ozkurt, ZubeydeSanz, JaimeBrissot, EoliaZina, PericGiebel, SebastianCiceri, FabioMohty, Mohamad2022-12-292022-12-292022https://journals.lww.com/hemasphere/Fulltext/2022/11000/Haploidentical_Versus_Matched_Sibling_Donor.3.aspxhttp://hdl.handle.net/11727/8479The results of haploidentical stem cell transplantation (haploHCT) for patients with acute lymphoblastic leukemia (ALL) transplanted in active disease remain largely unknown. We retrospectively analyzed adult patients with R/R ALL who underwent haploHCT or matched sibling donor (MSD-HCT) as a first transplantation between 2012 and 2020. The analysis comprised 274 patients, 94 had a haploHCT, and 180 had an MSD-HCT. The median follow-up was 32 months. The median age was 33 (range 18-76) and 37 (18-76) years in the haplo- and MSD-HCT groups, respectively. Post-transplant cyclophosphamide (PTCy) was used in 88% of haploHCT and in 4% of the MSD-HCT group. Graft-versus-host disease grade III-IV was higher in haploHCT than in the MSD-HCT group (18% versus 9%; P = 0.042). The 2-year chronic (c) graft-versus-host disease rates were 17% versus 33% (hazard ratio [HR] = 0.56; P = 0.14), respectively. By multivariate analysis, relapse incidence, and leukemia-free survival were not significatively different between the transplant groups, while nonrelapse mortality (NRM) was significantly higher (25% versus 18% at 2 years; HR = 2.03; P = 0.042) and overall survival (OS) lower (22% versus 38% at 2 years; HR = 1.72; P = 0.009) in the haploHCT group compared with the MSD-HCT group. We conclude that the 2-year OS of R/R ALL patients undergoing MSD transplants is significantly better than in haploHCT with a higher NRM in the latter.enginfo:eu-repo/semantics/openAccessarticle611000892089600008